US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

AI Healthcare

876.85

-19.9988-2.23%

Number of Gainers:2

Number of Losers:2

Number of Flat:- -

PE:- -

High:894.10

Open:892.90

Low:855.49

Close:896.85

Volume:80.02M

Turnover:1.12B

Market Cap:26.71B

Float Cap:19.95B

Loading ...

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM) and Disc Medicine (IRON)

2 Soaring Cathie Wood Stocks to Buy and Hold

CRISPR Therapeutics Plans to Sell Up to $600 Million in Common Stock

Whitehawk Shares Rise After Forming Collaboration With Tempus AI to Advance Oncology Research

MT Newswires Live

Is Recursion Pharmaceuticals a Millionaire Maker?

Tempus Announces Collaboration With WhiteHawk Therapeutics to Advance Biomarker-Driven Oncology Research

THOMSON REUTERS

New to Growth Stocks? Here's 1 Every Investor Should Have on Their Radar.

Tempus AI Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025

Recursion Pharmaceuticals call volume above normal and directionally bullish

4 biotech bargains with realistic upside

4 Healthcare Stocks to Buy Now

Recursion Pharmaceuticals CEO Christopher Gibson Reports Disposal of Common Shares

Nancy Pelosi, Cathie Wood Align On These 4 Stocks – Do You Own Any?

Benzinga_recent_news

Why Tempus AI (TEM) Is Up 11.2% After Securing ARPA-H Precision Cancer Therapy Collaboration

Simply Wall St.

Crispr Says CTX460 for Alpha-1 Antitrypsin Deficiency Treatment Shows 'Durable Effects' in Preclinical Studies

MT Newswires Live

Beam Therapeutics Inc : Jefferies Initiates Coverage With Buy Rating: Target Price $41

THOMSON REUTERS

Beam Therapeutics initiated with a Buy at Jefferies

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Tempus AI selected by ARPA-H to provide CRO services

BRIEF-Tempus AI Inc - Selected By ARPA-H To Provide CRO And Testing Services For The Adapt Program

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4611/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4611","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","market":"US","secType":"PLATE","nameCN":"AI Healthcare","latestPrice":876.85205,"timestamp":1760731199999,"preClose":896.8509,"halted":0,"volume":80020738,"delay":0,"changeRate":-0.022299,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-19.99884,"latestTime":"10-17 16:00:00 EDT","open":892.9043,"high":894.1037,"low":855.4857,"amount":1118760401.032594,"amplitude":0.04306,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1760947200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.860574,"peRate":-15.945622,"turnoverRate":0.114781,"increases":2,"decrements":2,"flats":0,"marketCap":26711343872,"floatMarketCap":19954693888},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","high":894.1037,"amplitude":0.04306,"preClose":896.8509,"low":855.4857,"pbRate":"6.860574","latestPrice":876.85205,"volume":80020738,"delay":0,"open":892.9043,"prevYearClose":530.4984,"prevWeekClose":921.6894,"prevMonthClose":803.2486,"prevQuarterClose":803.2486,"fiveDayClose":921.6894,"twentyDayClose":827.7748,"sixtyDayClose":742.0241,"secType":"PLATE","market":"US","turnoverRate":0.114781,"peRate":-15.945622,"marketCap":26711343872,"floatMarketCap":19954693888,"timestamp":1760731199999,"nameCN":"AI Healthcare"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4611\",,,,undefined,":{"bkCode":"BK4611","up":2,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4611\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576803785","title":"Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM) and Disc Medicine (IRON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2576803785","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576803785?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:50","pubTimestamp":1760701836,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Beam Therapeutics (BEAM – Research Report) and Disc ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-beam-therapeutics-beam-and-disc-medicine-iron-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-beam-therapeutics-beam-and-disc-medicine-iron-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4505","BK4581","XLV","LABU","LU0029874061.USD","BEAM","BK4585","IRON","HCSG","LU0128526141.USD","XBI","BK4588","BK4611","BK4556","BK4139","BK4535"],"gpt_icon":0},{"id":"2576208785","title":"2 Soaring Cathie Wood Stocks to Buy and Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2576208785","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576208785?lang=en_us&edition=fundamental","pubTime":"2025-10-17 16:45","pubTimestamp":1760690700,"startTime":"0","endTime":"0","summary":"These companies' market-beating fuel hasn't run out yet.","market":"us","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F837714%2Fscientist-altering-dna-genome-project.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F837714%2Fscientist-altering-dna-genome-project.jpg&op=resize&w=165&h=104"],"rights":{"source":"fool_stock","url":"https://www.fool.com/investing/2025/10/17/2-soaring-cathie-wood-stocks-to-buy-and-hold/","rn_cache_url":null,"customStyle":"","selectors":".main-contain, #article-page","filters":"#sticky-wrapper, .navigation, .article-page-end, .foot, .author-tagline, .author-inline, .footer, .soc-share, .wysiwyg, .related-content","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/10/17/2-soaring-cathie-wood-stocks-to-buy-and-hold/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4585","BK4523","TTM","SPOT","BK4556","BK4108","LU2362541273.HKD","LU1852331112.SGD","LU2362540622.SGD","LU2250418816.HKD","LU2360107168.USD","LU1861215975.USD","LU0786609619.USD","BK4588","BK4139","LU1861559042.SGD","BK4571","LU2098885051.SGD","LU0056508442.USD","LU1303367103.USD","LU2360106780.USD","LU1861220033.SGD","ARKK","BK4544","LU1861558580.USD","LU1804176565.USD","LU2265009873.SGD","LU2362541513.USD","BK4099","CRSP","LU2290526834.HKD","BK4548","LU1983260115.SGD","BK4611"],"gpt_icon":0},{"id":"1157690800","title":"CRISPR Therapeutics Plans to Sell Up to $600 Million in Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1157690800","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157690800?lang=en_us&edition=fundamental","pubTime":"2025-10-16 23:00","pubTimestamp":1760626859,"startTime":"0","endTime":"0","summary":"On Thursday morning, shares of gene-editing company CRISPR Therapeutics (CRSP) fell 1.7% after the company filed documents to sell up to $600 million in common stock, utilizing its existing public...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1861558580.USD","LU1861559042.SGD","BK4611","BK4585","CRSP","BK4556","BK4139"],"gpt_icon":0},{"id":"2575744129","title":"Whitehawk Shares Rise After Forming Collaboration With Tempus AI to Advance Oncology Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2575744129","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575744129?lang=en_us&edition=fundamental","pubTime":"2025-10-16 21:32","pubTimestamp":1760621574,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics  shares were sharply higher Thursday after the company formed a multi-year collaboration with Tempus AI  to leverage Tempus' real-world dataset to advance biomarker-driven research and further Whitehawk Therapeutics' oncology pipeline, Tempus said.The collaboration will focus on Whitehawk Therapeutics' antibody drug conjugates portfolio, which includes three assets designed to target proteins that are broadly expressed in high-potential cancer indications, such as lung and gynecological cancers, the company said.Shares of Tempus AI and Whitehawk were up 5.3% and 54.7%, respectively, in early trading.Price: 3.28, Change: +1.17, Percent Change: +55.45","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4611","TEM.AU","LU1861558580.USD","WHWK","BK7095","BK4139","BK4613","BK4121","LU1861559042.SGD","TEM"],"gpt_icon":1},{"id":"2575744178","title":"Is Recursion Pharmaceuticals a Millionaire Maker?","url":"https://stock-news.laohu8.com/highlight/detail?id=2575744178","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575744178?lang=en_us&edition=fundamental","pubTime":"2025-10-16 21:31","pubTimestamp":1760621460,"startTime":"0","endTime":"0","summary":"This is the only biotech stock to attract an investment from artificial intelligence (AI) giant Nvidia.","market":"fut","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F838073%2Fscientists-looking-at-screen-with-icons.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F838073%2Fscientists-looking-at-screen-with-icons.jpg&op=resize&w=165&h=104"],"rights":{"source":"fool_stock","url":"https://www.fool.com/investing/2025/10/16/is-recursion-pharmaceuticals-a-millionaire-maker/","rn_cache_url":null,"customStyle":"","selectors":".main-contain, #article-page","filters":"#sticky-wrapper, .navigation, .article-page-end, .foot, .author-tagline, .author-inline, .footer, .soc-share, .wysiwyg, .related-content","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/10/16/is-recursion-pharmaceuticals-a-millionaire-maker/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4528","BK4587","BK4023","BK4548","BK4588","BK4611","AI","BK4539","BK4585","BK4609","RXRX","BK4551","BK4139","BK4543"],"gpt_icon":1},{"id":"2575746943","title":"Tempus Announces Collaboration With WhiteHawk Therapeutics to Advance Biomarker-Driven Oncology Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2575746943","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575746943?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:30","pubTimestamp":1760617800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nTUABMXCJW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","TEM","LU1861558580.USD","BK4611","LU1861559042.SGD","BK4613"],"gpt_icon":0},{"id":"2575718045","title":"New to Growth Stocks? Here's 1 Every Investor Should Have on Their Radar.","url":"https://stock-news.laohu8.com/highlight/detail?id=2575718045","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575718045?lang=en_us&edition=fundamental","pubTime":"2025-10-16 16:10","pubTimestamp":1760602200,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics is a promising mid-cap biotech stock with an approved product in its portfolio.","market":"fut","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F832965%2Fbusinessman-with-a-chart-looking-at-his-computer.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F832965%2Fbusinessman-with-a-chart-looking-at-his-computer.jpg&op=resize&w=165&h=104"],"rights":{"source":"fool_stock","url":"https://www.fool.com/investing/2025/10/16/growth-stocks-investor-radar-crsp-crispr/","rn_cache_url":null,"customStyle":"","selectors":".main-contain, #article-page","filters":"#sticky-wrapper, .navigation, .article-page-end, .foot, .author-tagline, .author-inline, .footer, .soc-share, .wysiwyg, .related-content","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/10/16/growth-stocks-investor-radar-crsp-crispr/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4585","BK4588","BK4611","CAGR","BK4556","LU1861559042.SGD","LU1861558580.USD","CRSP","BK4139","BK4159"],"gpt_icon":0},{"id":"2575578237","title":"Tempus AI Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575578237","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575578237?lang=en_us&edition=fundamental","pubTime":"2025-10-15 20:30","pubTimestamp":1760531434,"startTime":"0","endTime":"0","summary":"Tempus AI Inc. has announced that six abstracts have been accepted for presentation at the upcoming European Society for Medical Oncology  Congress 2025, scheduled to take place from October 17-21 in Berlin, Germany. Among these, two are oral presentations and four are poster presentations. One of the oral presentations will focus on the efficacy of cabozantinib and nivolumab in Cluster 1/2 metastatic clear cell renal cell carcinoma, with results from the phase II OPTIC RCC trial featuring a novel RNAseq-based biomarker. Another research summary to be presented examines real-world data from 2,173 patients with metastatic castration-sensitive prostate cancer  sequenced using the Tempus xT DNA assay. This analysis found that patients with a high burden of tumor suppressor gene alterations had inferior overall survival outcomes following first-line therapy. These findings will be presented at ESMO Congress 2025.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL6m0dcP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","TEM","LU1861559042.SGD","BK4613","BK4121","LU1861558580.USD"],"gpt_icon":1},{"id":"2575124926","title":"Recursion Pharmaceuticals call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2575124926","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575124926?lang=en_us&edition=fundamental","pubTime":"2025-10-15 02:45","pubTimestamp":1760467511,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 26,086 calls trading, 1.1x expected, and implied vol increasing almost 32 poi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-call-volume-above-normal-and-directionally-bullish-thefly-7?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-call-volume-above-normal-and-directionally-bullish-thefly-7?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","BK4609","RXRX","BK4611","BK4548"],"gpt_icon":0},{"id":"2575402094","title":"4 biotech bargains with realistic upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2575402094","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575402094?lang=en_us&edition=fundamental","pubTime":"2025-10-13 11:38","pubTimestamp":1760326697,"startTime":"0","endTime":"0","summary":"As the broader market is looking increasingly expensive and concentrated, Orbis has been looking for value in undervalued sectors, such as biotech. In its latest Quarterly Commentary, Orbis takes a closer look at four of these opportunities. This article was first published on 30 September 2025.Investing is ultimately about the balance between price and value—what you pay versus what you get. Most often, “value” depends on uncertain future outcomes, and the key risk is overpaying for a flock of expensive birds in a distant bush. Far more compelling are those rare opportunities to buy at deeply discounted prices that give little or no credit to future upside.At a time when the broader market looks increasingly expensive and concentrated, we’ve been able to find deeply undervalued and idiosyncratic opportunities in select biotech shares. During the pandemic, investors eagerly funnelled capital into the sector, but since then their attention – and their money – has shifted to the shiny ne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/4-biotech-bargains-with-realistic-upside","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/4-biotech-bargains-with-realistic-upside","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK4023","BK4585","SQQQ","BK4556","USJW.SI","LU0109394709.USD","ALNY","BK4595","BK4600","QID","BK4548","TQQQ","BK4516","LU0320765992.SGD","BK4588","BK4139","LU0889565916.HKD","LU1861559042.SGD","NVIW.SI","STRK","GMAB","TSYW.SI","USAW.SI","BK4596","LU1861558580.USD","LU0053671581.USD","PSQ","QLD","CRSP","MNQmain","NQmain","INSM",".IXIC","BK4611"],"gpt_icon":1},{"id":"2574418735","title":"4 Healthcare Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2574418735","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574418735?lang=en_us&edition=fundamental","pubTime":"2025-10-12 21:45","pubTimestamp":1760276700,"startTime":"0","endTime":"0","summary":"As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.","market":"fut","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F837439%2Fbiotech-researcher.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F837439%2Fbiotech-researcher.jpg&op=resize&w=165&h=104"],"rights":{"source":"fool_stock","url":"https://www.fool.com/investing/2025/10/12/4-healthcare-stocks-to-buy-now/","rn_cache_url":null,"customStyle":"","selectors":".main-contain, #article-page","filters":"#sticky-wrapper, .navigation, .article-page-end, .foot, .author-tagline, .author-inline, .footer, .soc-share, .wysiwyg, .related-content","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/10/12/4-healthcare-stocks-to-buy-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4588","XBI","BK4581","LU1861558580.USD","XLV","LU1861559042.SGD","BK4611","BK4585","LABU","CRSP","HCSG","BK4556","BK4137","BK4139"],"gpt_icon":0},{"id":"2574483647","title":"Recursion Pharmaceuticals CEO Christopher Gibson Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2574483647","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574483647?lang=en_us&edition=fundamental","pubTime":"2025-10-11 06:03","pubTimestamp":1760133827,"startTime":"0","endTime":"0","summary":"Christopher Gibson, Chief Executive Officer and Director of Recursion Pharmaceuticals Inc., has reported the disposal of common shares of the company, according to a recent SEC filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL73spQg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RXRX","BK4539","BK4548","BK4611","BK4609"],"gpt_icon":1},{"id":"2574886334","title":"Nancy Pelosi, Cathie Wood Align On These 4 Stocks – Do You Own Any?","url":"https://stock-news.laohu8.com/highlight/detail?id=2574886334","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574886334?lang=en_us&edition=fundamental","pubTime":"2025-10-11 05:03","pubTimestamp":1760130180,"startTime":"0","endTime":"0","summary":"Shared stocks between Nancy Pelosi and Cathie Wood include Alphabet, Amazon, NVIDIA, and Tempus AI. They also both own stakes in private company Databricks.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/10/Armenia--Yerevan-18-September-2022-U-s--.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/10/Armenia--Yerevan-18-September-2022-U-s--.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/long-ideas/25/10/48162138/nancy-pelosi-cathie-wood-align-on-these-4-stocks-do-you-own-any","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/long-ideas/25/10/48162138/nancy-pelosi-cathie-wood-align-on-these-4-stocks-do-you-own-any","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["GOOGL","NVDX","NQmain","IE00BN29S564.USD","TQQQ","QLD","LU1261432733.SGD","LU1032955483.USD","NVD","LU2294711713.HKD","GOOG","SQQQ","LU0289961442.SGD","LU2097829019.USD","TSYW.SI",".IXIC","IE00BWXC8680.SGD","NVD2.UK","LU0985489474.SGD","LU0215105999.USD","NVDS.UK","SG9999018865.SGD","NVDD","NVDS","LU0648001328.SGD","LU0061474960.USD","AMZN","MNQmain","BK4611","TEM","LU2764262908.HKD","NVIW.SI","USAW.SI","3NVD.UK","USJW.SI","LU1720051108.HKD","NVDU","NVDY","QID","2NVD.UK","SNVD.UK","LU0878866978.SGD","NVDA","PSQ","LU1983260115.SGD","LU2543165471.USD","ARKK","NVD3.UK"],"gpt_icon":1},{"id":"2574485960","title":"Why Tempus AI (TEM) Is Up 11.2% After Securing ARPA-H Precision Cancer Therapy Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2574485960","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574485960?lang=en_us&edition=fundamental","pubTime":"2025-10-11 02:23","pubTimestamp":1760120599,"startTime":"0","endTime":"0","summary":"Tempus AI, Inc. announced it has been selected by the U.S. Department of Health and Human Services' Advanced Research Projects Agency for Health (ARPA-H) to provide AI-enabled diagnostics and contract research services for the ADAPT precision cancer therapy program targeting metastatic lung, breast, and colorectal cancers.\nThe collaboration not only highlights Tempus AI's pivotal role in government-backed precision medicine initiatives but also showcases its multi-omics capabilities and data...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/why-tempus-ai-tem-is-up-112-after-securing-arpa-h-precision","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/why-tempus-ai-tem-is-up-112-after-securing-arpa-h-precision","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TEM","BK7095","BK4121","BK4528","BK4551","BK4585","BK4587","BK4611","BK4543","BK4588","BK4023","BK4613","LU1861558580.USD","LU1861559042.SGD","TEM.AU"],"gpt_icon":1},{"id":"2574351179","title":"Crispr Says CTX460 for Alpha-1 Antitrypsin Deficiency Treatment Shows 'Durable Effects' in Preclinical Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2574351179","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574351179?lang=en_us&edition=fundamental","pubTime":"2025-10-10 20:55","pubTimestamp":1760100906,"startTime":"0","endTime":"0","summary":"Crispr Therapeutics  said Friday that its alpha-1 antitrypsin deficiency treatment program, called CTX460, showed \"specific and durable effects\" in preclinical studies.Data demonstrated that a single dose of CTX460 resulted in significant, dose-dependent correction of liver deoxyribonucleic acid or DNA in both rat and mouse AATD models, as well as over 90% messenger ribonucleic acid or mRNA correction at a clinically relevant dose of 0.5 mg/kg in PiZ mice.Additionally, the durability of gene editing with CTX460 was maintained in both rat and mouse models for up to seven and nine weeks, respectively, the company said.Crispr Therapeutics said it plans to conduct a clinical trial with CTX460 in mid-2026.Shares of the company were up 4% in recent Friday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1861558580.USD","CRSP","LU1861559042.SGD","BK4139","BK4588","BK4585","BK4556","BK4611"],"gpt_icon":0},{"id":"2574149000","title":"Beam Therapeutics Inc : Jefferies Initiates Coverage With Buy Rating: Target Price $41","url":"https://stock-news.laohu8.com/highlight/detail?id=2574149000","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574149000?lang=en_us&edition=fundamental","pubTime":"2025-10-10 13:53","pubTimestamp":1760075624,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nFWN3VR13N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BEAM","BK4139","BK4535","BK4556","BK4505","BK4611","BK4588","BK4585"],"gpt_icon":0},{"id":"2574277164","title":"Beam Therapeutics initiated with a Buy at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2574277164","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574277164?lang=en_us&edition=fundamental","pubTime":"2025-10-09 23:45","pubTimestamp":1760024721,"startTime":"0","endTime":"0","summary":"Jefferies initiated coverage of Beam Therapeutics (BEAM) with a Buy rating and $41 price target The firm, which believes BEAM-302 for Alpha-1 Antit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-initiated-with-a-buy-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-initiated-with-a-buy-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BEAM","BK4505","BK4007","BK4556","BK4535","BK4611","BK4139","BK4588","LENZ","BK4539","BK4585"],"gpt_icon":0},{"id":"2574161742","title":"Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2574161742","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574161742?lang=en_us&edition=fundamental","pubTime":"2025-10-09 23:01","pubTimestamp":1760022060,"startTime":"0","endTime":"0","summary":"Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse modelsCAMBRIDGE, Mass., Oct.  09, 2025  (GLOBE NEWSWIRE) -- Editas Medicine, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/09/3164355/0/en/Editas-Medicine-Reports-In-Vivo-Proof-of-Concept-Data-for-EDIT-401-at-the-European-Society-of-Gene-and-Cell-Therapy-ESGCT-32nd-Annual-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRSP","EDIT","BK4585","BK4556","BK4139","LU1861558580.USD","LU1861559042.SGD","BK4588","PACI.U","BK4611"],"gpt_icon":0},{"id":"2574509861","title":"Tempus AI selected by ARPA-H to provide CRO services","url":"https://stock-news.laohu8.com/highlight/detail?id=2574509861","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574509861?lang=en_us&edition=fundamental","pubTime":"2025-10-09 20:55","pubTimestamp":1760014520,"startTime":"0","endTime":"0","summary":"Tempus AI (TEM) announced it has been selected by the Advanced Research Projects Agency for Health, an agency within the U.S. Department of Health ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempus-ai-selected-by-arpa-h-to-provide-cro-services-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempus-ai-selected-by-arpa-h-to-provide-cro-services-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861559042.SGD","BK4023","BK4588","BK4121","BK4551","TEM","BK4611","BK4585","BK4613","LU1861558580.USD","BK4587","BK4543","BK4528"],"gpt_icon":0},{"id":"2574001152","title":"BRIEF-Tempus AI Inc - Selected By ARPA-H To Provide CRO And Testing Services For The Adapt Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2574001152","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574001152?lang=en_us&edition=fundamental","pubTime":"2025-10-09 20:33","pubTimestamp":1760013227,"startTime":"0","endTime":"0","summary":"BRIEF-Tempus AI Inc - Selected By ARPA-H To Provide CRO And Testing Services For The Adapt ProgramOct 9 (Reuters) - Tempus AI Inc TEM.O:TEMPUS AI INC - SELECTED BY ARPA-H TO PROVIDE CRO AND TESTING SE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nFWN3VP2GM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEM","LU1861559042.SGD","BK4613","LU1861558580.USD","BK4121","BK4611"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}]}}